Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Kestra Medical Technologies, Ltd. filed a notice of proposed sale of restricted securities. The filing covers a planned sale of 26,287 shares of common stock through Merrill Lynch, with an aggregate market value of $680,383.99, when the issuer had approximately 58,602,497 shares of common stock outstanding. The securities relate to performance share unit awards that vested on July 14, 2026 and were granted under the issuer’s equity compensation plan.
The reporting security holder, Vaseem Mahboob, also lists prior sales of common stock during the past three months: 3,980 shares on July 30, 2026 for $90,560.62; 8,817 shares on July 31, 2026 for $199,344.62; 5,391 shares on August 3, 2026 for $128,312.27; and 6,995 shares on August 4, 2026 for $172,634.70.
Kestra Medical Technologies Chief Commercial Officer Alfred J. Ford Jr. reported a nondiscretionary sale of 6,275 common shares on 2026-08-04 to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. The shares were sold at a weighted average price of $24.0862, with prices ranging from $23.9000 to $24.5700. Following this tax-related sale, he directly holds 99,564 common shares of Kestra Medical Technologies.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported selling 6,995 common shares on August 4, 2026. A sale of 3,080 shares at a weighted average $24.057 was a nondiscretionary sell-to-cover for RSU tax withholding, and a separate 3,915-share sale at $25.1696 occurred under a Rule 10b5-1 trading plan adopted November 6, 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. executive Traci S. Umberger, General Counsel and Chief Administrative Officer, reported a non-discretionary sale of 3,580 common shares on August 4, 2026, to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The sale was executed at a weighted average price of $24.0428 per share, with individual prices ranging from $23.8000 to $24.4200.
Following this tax-related sale, Umberger directly holds 195,825 common shares of Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd.'s President and Chief Executive Officer, Brian Daniel Webster, reported selling 51,900 common shares of KMTS on August 4, 2026, across three sale transactions. Footnotes state these were nondiscretionary sell-to-cover sales to satisfy tax withholding obligations from restricted stock unit vesting, including 48,625 shares at a weighted average price of $24.4692 per share.
Kestra Medical Technologies, Ltd. reports a planned sale of up to 51,900 common shares through Merrill Lynch on NASDAQ, with an aggregate value of $1,272,585.45. The shares relate to a 07/17/2026 performance stock issuance granted under an equity compensation plan and follow multiple prior common share sales over recent months.
Kestra Medical Technologies, Ltd. (KMTS) has a proposed sale of 3,580 shares of common stock through Merrill Lynch on 08/04/2026, following the 07/17/2026 vesting of restricted stock unit awards granted as equity compensation. The Form 144 also lists prior sales over the last three months by reporting person Traci Umberger.
Kestra Medical Technologies, Ltd. insider Alfred J. Ford filed notice of a planned sale of 6,275 shares of common stock through Merrill Lynch on NASDAQ on 08/04/2026, with an indicated value of $151,140.78. These shares relate to restricted stock units that vest on 07/17/2026 under the issuer’s equity compensation plan.
Over the prior three months, Alfred J. Ford reported sales of 5,936 shares for $135,120.73 on 07/30/2026, 8,681 shares for $196,284.58 on 07/31/2026, and 13,015 shares for $311,118.83 on 08/03/2026.
Kestra Medical Technologies, Ltd. has a planned sale of 6,995 shares of common stock through Merrill Lynch on NASDAQ on 08/04/2026. These shares relate to the 07/17/2026 vesting of performance share unit awards granted under the issuer’s equity compensation plan.
The filing also lists prior sales by Vaseem Mahboob over the past three months: 3,980 shares on 07/30/2026 for 90,560.62, 8,817 shares on 07/31/2026 for 199,344.62, and 5,391 shares on 08/03/2026 for 128,312.27.
Kestra Medical Technologies Chief Business Officer Timothy P. Moran reported nondiscretionary sales of 15,256 common shares to cover tax withholding arising from vested restricted stock units. The shares were sold on July 30, July 31 and August 3, 2026 at weighted average prices of $22.7735, $22.6054 and $23.7611 per share within intraday ranges from $22.15 to $23.98.